MovDisordV3, Ncbi, Merge, bibRecord, 000955

Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.

Identifieur interne : 000955 ( Ncbi/Merge ); précédent : 000954; suivant : 000956

Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.

Auteurs : Jakob Christensen [Danemark] ; Erik Dupont ; Karen Stergaard

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.

RBID : pubmed:12465083

English descriptors

KwdEn :
- Adult, Aged, Antifungal Agents (administration & dosage), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacokinetics), Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme Inhibitors, Dose-Response Relationship, Drug, Drug Interactions, Drug Therapy, Combination, Ergolines (administration & dosage), Ergolines (pharmacokinetics), Female, Humans, Itraconazole (administration & dosage), Male, Neurologic Examination (drug effects), Onychomycosis (blood), Onychomycosis (drug therapy), Parkinson Disease (blood), Parkinson Disease (drug therapy), Treatment Outcome.
MESH :
- chemical , administration & dosage : Antifungal Agents, Antiparkinson Agents, Ergolines, Itraconazole.
- chemical , pharmacokinetics : Antiparkinson Agents, Ergolines.
- blood : Onychomycosis, Parkinson Disease.
- drug effects : Neurologic Examination.
- drug therapy : Onychomycosis, Parkinson Disease.
- Adult, Aged, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme Inhibitors, Dose-Response Relationship, Drug, Drug Interactions, Drug Therapy, Combination, Female, Humans, Male, Treatment Outcome.

Abstract

We report on 2 patients with idiopathic Parkinson's disease who experienced marked improvement in symptoms following the addition of itraconazole to current cabergoline treatment. Plasma levels of cabergoline were analyzed in one of the patients and increased to approximately 300% during treatment with itraconazole, which paralleled major clinical improvement.

DOI: 10.1002/mds.10250
PubMed: 12465083

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003896
to stream PubMed, to step Curation: 003896
to stream PubMed, to step Checkpoint: 003B73

Links to Exploration step

pubmed:12465083

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.</title>
<author><name sortKey="Christensen, Jakob" sort="Christensen, Jakob" uniqKey="Christensen J" first="Jakob" last="Christensen">Jakob Christensen</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Clinical Pharmacology, University of Aarhus, Aarhus, Denmark. Jakob@farm.au.dk</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Centre for Clinical Pharmacology, University of Aarhus, Aarhus</wicri:regionArea>
<wicri:noRegion>Aarhus</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name>
</author>
<author><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen  Stergaard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12465083</idno>
<idno type="pmid">12465083</idno>
<idno type="doi">10.1002/mds.10250</idno>
<idno type="wicri:Area/PubMed/Corpus">003896</idno>
<idno type="wicri:Area/PubMed/Curation">003896</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B73</idno>
<idno type="wicri:Area/Ncbi/Merge">000955</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.</title>
<author><name sortKey="Christensen, Jakob" sort="Christensen, Jakob" uniqKey="Christensen J" first="Jakob" last="Christensen">Jakob Christensen</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Clinical Pharmacology, University of Aarhus, Aarhus, Denmark. Jakob@farm.au.dk</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Centre for Clinical Pharmacology, University of Aarhus, Aarhus</wicri:regionArea>
<wicri:noRegion>Aarhus</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name>
</author>
<author><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen  Stergaard</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antifungal Agents (administration & dosage)</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Cytochrome P-450 CYP3A</term>
<term>Cytochrome P-450 Enzyme Inhibitors</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Ergolines (administration & dosage)</term>
<term>Ergolines (pharmacokinetics)</term>
<term>Female</term>
<term>Humans</term>
<term>Itraconazole (administration & dosage)</term>
<term>Male</term>
<term>Neurologic Examination (drug effects)</term>
<term>Onychomycosis (blood)</term>
<term>Onychomycosis (drug therapy)</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antifungal Agents</term>
<term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Itraconazole</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Onychomycosis</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Onychomycosis</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cytochrome P-450 CYP3A</term>
<term>Cytochrome P-450 Enzyme Inhibitors</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Interactions</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report on 2 patients with idiopathic Parkinson's disease who experienced marked improvement in symptoms following the addition of itraconazole to current cabergoline treatment. Plasma levels of cabergoline were analyzed in one of the patients and increased to approximately 300% during treatment with itraconazole, which paralleled major clinical improvement.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12465083</PMID>
<DateCreated><Year>2002</Year>
<Month>12</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>17</Volume>
<Issue>6</Issue>
<PubDate><Year>2002</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.</ArticleTitle>
<Pagination><MedlinePgn>1360-2</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We report on 2 patients with idiopathic Parkinson's disease who experienced marked improvement in symptoms following the addition of itraconazole to current cabergoline treatment. Plasma levels of cabergoline were analyzed in one of the patients and increased to approximately 300% during treatment with itraconazole, which paralleled major clinical improvement.</AbstractText>
<CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Christensen</LastName>
<ForeName>Jakob</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Centre for Clinical Pharmacology, University of Aarhus, Aarhus, Denmark. Jakob@farm.au.dk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dupont</LastName>
<ForeName>Erik</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>ØStergaard</LastName>
<ForeName>Karen</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065607">Cytochrome P-450 Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>304NUG5GF4</RegistryNumber>
<NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="C104464">CYP3A protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.14.1</RegistryNumber>
<NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>LL60K9J05T</RegistryNumber>
<NameOfSubstance UI="C047047">cabergoline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000935">Antifungal Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D051544">Cytochrome P-450 CYP3A</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D065607">Cytochrome P-450 Enzyme Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004873">Ergolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017964">Itraconazole</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014009">Onychomycosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>12</Month>
<Day>5</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>3</Month>
<Day>26</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>12</Month>
<Day>5</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12465083</ArticleId>
<ArticleId IdType="doi">10.1002/mds.10250</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Danemark</li>
</country>
</list>
<tree><noCountry><name sortKey=" Stergaard, Karen" sort=" Stergaard, Karen" uniqKey=" Stergaard K" first="Karen" last=" Stergaard">Karen  Stergaard</name>
<name sortKey="Dupont, Erik" sort="Dupont, Erik" uniqKey="Dupont E" first="Erik" last="Dupont">Erik Dupont</name>
</noCountry>
<country name="Danemark"><noRegion><name sortKey="Christensen, Jakob" sort="Christensen, Jakob" uniqKey="Christensen J" first="Jakob" last="Christensen">Jakob Christensen</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000955 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000955 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:12465083
   |texte=   Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:12465083" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.

Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki